Eli Lilly is the dominant player in incretin obesity and diabetes care. Tirzepatide — Mounjaro for type-2 diabetes, Zepbound for obesity — generated the bulk of 2025 growth, and SURMOUNT-5, the first definitive Phase 3B head-to-head against semaglutide, read out 21.6% mean weight loss at 72 weeks versus semaglutide's 15.4%. Q1 2026 revenue reached $19.8 billion (+56% YoY) on Mounjaro $8.66B (+125%) and Zepbound $4.16B (+80%); Lilly raised 2026 guidance to $82–85B on April 30 and the stock climbed 6.11% on May 1. On May 4, an FAERS hepatic-failure case for Foundayo surfaced, sending shares down 3% premarket before recovering on Lilly's safety-data response and an RBC 'baseline noise' defense.
The next layer determines 2027 and beyond. Orforglipron, marketed as Foundayo, became the first small-molecule oral GLP-1 cleared for obesity in April 2026 and reached roughly 20,000 patients and more than 8,000 prescribers in its first three weeks, though Wegovy pill outpaced it ~20× in early-May IQVIA volume. Retatrutide, the GLP-1/GIP/glucagon triple agonist, posted its first Phase 3 type-2 diabetes readout (TRANSCEND T2D1: A1c down 1.7–2.0 pts, 25–37 lb mean weight loss) on the April 30 call alongside the prior TRIUMPH-4 obesity-with-knee-osteoarthritis data. The retatrutide MASLD Phase 3 (NCT06859268) is enrolling, building on 86% Phase 2 liver-fat reduction. LillyDirect handles self-pay distribution.
The company has spent 2024 and 2025 building peptide CDMO capacity to support both branded volume and the long shadow of the compounding fight. June 2026 forced a manufacturing geography rethink: Lilly halved its planned €2.3 billion ($2.7B) Alzey, Rhineland-Palatinate injectable plant to roughly €1.15 billion and cut planned headcount from 1,000 to 500, citing Germany's proposed 'dynamic manufacturer rebate' and the broader healthcare-reform package. The redirected capital is heading to US sites, most likely Lilly's Pennsylvania facility, alongside the previously announced $4.5 billion Indiana 'Medicine Foundry' R&D and manufacturing project. Boehringer Ingelheim is making a parallel German cut. The Alzey scale-back arrived the same week as STAT News' June 23 disclosure that the FDA and Lilly granted compassionate-use retatrutide access to a 79-year-old patient on the application of NIH senior clinician Dr. Ranganath Muniyappa, with the White House publicly denying that President Trump applied. Stories here track the pipeline, deals, manufacturing geography, and the share-price moves that follow them.
PolitiFact published a primer piece Wednesday July 1, 2026 titled 'A primer on retatrutide and compassionate use,' laying out the underlying facts of the STAT News June 23 disclosure for readers coming to the story after two weeks of political-controversy coverage. The primer format explained: what compassionate use is (the FDA's expanded-access single-patient IND pathway, 21 CFR 312 Subpart I, ~1,800 requests per year at 99%+ approval); what retatrutide is (Eli Lilly's investigational GLP-1/GIP/glucagon triple agonist, still in Phase 3, TRIUMPH-1 topline 28.3% mean weight loss at 12 mg over 80 weeks); the STAT News reporting timeline (June 23 initial scoop by Lizzy Lawrence, June 25 Senator Hassan letter, June 26 Rep. Ted Lieu press conference, June 29 White House pushback); and what remains unconfirmed (the patient's identity, Lilly's specific rationale for granting the compassionate-use request, whether the White House denial framing constitutes a categorical denial or a non-denial). PolitiFact did not confirm the patient's identity and did not issue a rating on any specific claim; the piece functions as fact-based reference material for the broader public conversation. The primer format is likely to circulate as the reference PolitiFact link for future stories on the case.
Medscape published 'Unapproved Retatrutide Use Challenges Clinicians' on Friday June 26, 2026, documenting the scale of gray-market and clinic-channel retatrutide use that runs parallel to Eli Lilly's Phase 3 TRIUMPH program. Two anchor data points: retatrutide exposures reported to US poison-control centers averaged 95 cases per month in Q1 2026, a 265% increase from the average across the last four months of 2025; and at least 50 US clinics staffed by licensed physicians and nurse practitioners openly advertise the unapproved drug to weight-loss patients. The piece frames the practical challenge for primary-care and obesity-medicine clinicians whose patients arrive already taking retatrutide sourced from research-chemical vendors, online clinics, or compounding pharmacies operating outside the FDA bulks-list framework. The Drug Topics companion story (same week) added that the prescribing rate is 'alarming' to obesity-medicine specialty groups. The data lands the same week as Senator Hassan's June 25 letter to HHS Secretary RFK Jr. demanding answers on the FDA-Lilly compassionate-use grant to a 79-year-old patient: one VIP-adjacent individual received the real drug through a sanctioned pathway while at least 50 clinics distribute the unregulated version at scale.
Gene-editing pioneer Sangamo Therapeutics filed a voluntary Chapter 11 petition in the US Bankruptcy Court for the District of Delaware on Monday June 23, 2026, after disclosing only $27.6 million in cash as of March 31 and a May 2026 Nasdaq delisting for minimum-bid-price non-compliance. Two simultaneous asset purchase agreements established the floor. Eli Lilly is the stalking-horse bidder at $50 million cash plus assumption of certain liabilities for Sangamo's capsid delivery platform, zinc finger platform, modular integrase (MINT) platform, and prion disease program ST-506. Astellas Pharma takes the Fabry disease asset isaralgagene civaparvovec (ST-920) under a separate agreement. The Lilly bid covers the assets most relevant to the peptide-adjacent neurology pipeline, with prion protein biology offering platform optionality for Lilly's broader neurodegeneration program. Both agreements remain subject to higher-or-better offers under standard Section 363 sale procedures. Sangamo simultaneously cut 51 employees, approximately 40% of its remaining workforce, with the remainder retained through the auction and sale process. The bankruptcy closes a 30-year arc that began as the zinc-finger nuclease pioneer through gene editing's commercial first wave, and underscores that gene-editing platform capital is now consolidating into large-pharma hands.
In addition to the political escalation (Senator Hassan's June 25 letter to RFK Jr.; Rep. Ted Lieu's June 24 terminal-illness press conference; White House counterattacks against STAT reporter Lizzy Lawrence and Lieu), STAT News reported that 18 bioethics experts, obesity-medicine clinicians, and current and former US government health officials told the outlet that Eli Lilly's decision to grant compassionate-use access to retatrutide for a single 79-year-old patient with refractory obesity, obstructive sleep apnea, and pulmonary hypertension 'struck them as unusual.' The core question raised by the bioethics community: why Lilly would offer compassionate use for a single patient when obesity is a population-scale condition affecting more than 100 million Americans, when expanded-access programs are typically structured around treatment INDs or intermediate-size protocols for broader access, and when the standard pathway for obesity-drug access is trial enrollment (TRIUMPH-2 obesity+T2D and TRIUMPH-3 obesity+CVD remain open). Jamy Ard (chief science officer, Advocate Health) said compassionate use is typically reserved for terminal illness. The bioethics critique is separate from the Trump-recipient speculation and is likely the more durable framing of the case as it moves through congressional oversight.
Senator Maggie Hassan (D-NH), ranking Democrat on the relevant committee, sent a formal written letter to HHS Secretary Robert F. Kennedy Jr. on June 25, 2026, demanding answers about whether President Trump (who turned 80 on June 14) is the 79-year-old patient who received compassionate-use access to Eli Lilly's investigational retatrutide. Hassan wrote: 'Reporting suggests that you have used this pathway to provide a highly anticipated medication for obesity to a single VIP individual for free, without providing that opportunity to other Americans.' Hassan also questioned Kennedy at a Senate committee hearing earlier the same day about 'vanity projects' at HHS. The June 25 letter is the first formal congressional action on the compassionate-use case originally reported by STAT News on June 23. Eli Lilly issued its first public statement to STAT News on June 25: 'We make these decisions following all applicable regulations.' The company has not disclosed how it evaluates retatrutide expanded-access requests or whether other applications are pending. Outside experts continue to question whether refractory obesity plus obstructive sleep apnea plus pulmonary hypertension meets the FDA's 'serious or immediately life-threatening' threshold typically reserved for terminal illness. The Senate letter creates an oversight track parallel to the political controversy already running through cable news and X.
The 2026 BIO International Convention closed Thursday June 25 at the San Diego Convention Center after four days, 20,000+ industry leaders in attendance, 130+ sessions across 18 focus areas, and a partnering-meeting volume that BIO sources said matched or exceeded prior-year records. Peptide-relevant headline deals across the convention week: the Insilico Medicine + SK Biopharmaceuticals $2.5 billion AI-neuroimmune drug discovery deal on Day 1 (June 22, $18M upfront + $670M per program in development and commercial milestones); BioArctic + Eli Lilly $800 million BrainTransporter blood-brain barrier delivery pact on Day 2 (June 23); STAT News' Day-3 BIO Readout column behind-the-scenes coverage of Eli Lilly's January Chai Discovery AI biologics partnership (June 24); and the disclosed Lilly-Astellas joint stalking-horse bid for Sangamo Therapeutics assets in bankruptcy (capsid delivery platform, zinc finger platform, modular integrase platform, prion disease program ST-506; Astellas takes Fabry disease asset isaralgagene civaparvovec). Fujifilm Life Sciences showcased a continuous electroporation gene delivery system and high-sensitivity in-line Raman measuring system at its Innovation Showcase. BIO 2027 returns to Boston June 7-10, 2027.
Eli Lilly confirmed in reporting on June 22-23, 2026 that it is halving its planned €2.3 billion (US$2.7 billion) investment at the under-construction Alzey, Rhineland-Palatinate injectable manufacturing site, reducing planned headcount from approximately 1,000 to 500 and pushing the redirected capital toward US sites, most likely Lilly's Pennsylvania facility. The plant produces injectable GLP-1 drugs Mounjaro (tirzepatide for type-2 diabetes), Zepbound (tirzepatide for obesity), and Trulicity (dulaglutide), and is still scheduled to open in 2027 at the reduced capacity. Lilly cited Germany's proposed healthcare reform legislation, particularly a 'dynamic manufacturer rebate' that would automatically lower drug reimbursements as utilization climbs. Boehringer Ingelheim is also slashing planned German investment by at least $1 billion, and Pfizer CEO Albert Bourla has signaled a reassessment. Lilly's CEO David Ricks told the German government the company 'can no longer commit to the full vision for Alzey.' The cut arrives the same week as STAT's retatrutide compassionate-use story, sharpening the contrast between Lilly's expanding US capital deployment and tightening European pricing.
STAT News' June 24, 2026 BIO Readout column (Damian Garde, Allison DeAngelis) delivered behind-the-scenes detail on Eli Lilly's January 9, 2026 collaboration with AI startup Chai Discovery for biologics design, plus an update on the Lilly-Astellas joint bid for Sangamo Therapeutics assets in bankruptcy. The Chai Discovery deal deploys the company's Chai-2 zero-shot antibody design model (reportedly achieving double-digit experimental hit rates and full de novo design capability) plus a purpose-built generative AI model trained exclusively on proprietary Lilly data and tailored to Lilly's discovery workflows. Chai closed a $130 million Series B at $1.3 billion valuation in late 2025, eighteen months after launch. On the Sangamo front, Lilly is in line to acquire Sangamo's capsid delivery platform, zinc finger platform, modular integrase platform, and prion disease program ST-506 in the bankruptcy auction; Astellas is positioned to take Fabry disease asset isaralgagene civaparvovec. BIO 2026 runs June 22-25 at the San Diego Convention Center.
STAT News broke June 23, 2026 that the FDA and Eli Lilly approved a single 79-year-old patient for compassionate-use access to retatrutide (Lilly's GIP/GLP-1/glucagon triple agonist still in Phase 3 development). Dr. Ranganath Muniyappa, a senior clinician at the National Institutes of Health, submitted the application in April citing diagnoses of refractory obesity, obstructive sleep apnea, and pulmonary hypertension. Outside medical experts told STAT the diagnoses don't clearly meet the compassionate-use threshold typically reserved for immediately life-threatening illness; Jamy Ard (chief science officer, Advocate Health) said 'compassionate use is usually reserved for terminal illness.' Compassionate use programs typically serve patients facing imminent death without alternatives, not refractory obesity even with severe comorbidities. The White House had to publicly deny that President Trump submitted the application. The patient's identity has not been confirmed. The episode crystallizes the peptide-access-equity tension at a moment when the broader US population continues to source retatrutide through gray-market research-chemical channels with no oversight.
BioArctic (Nasdaq Stockholm: BIOA b) announced on June 22, 2026 a research and collaboration agreement with Eli Lilly combining BioArctic's proprietary BrainTransporter technology — transferrin-receptor-mediated active transport across the blood-brain barrier — with an undisclosed Lilly proprietary molecule in neurodegeneration. BioArctic receives $30M upfront, eligibility for milestone payments up to $770M (total potential value ~$800M), plus tiered mid-single-digit royalties on global net sales. BioArctic will generate the new drug candidate combining the technology with Lilly's molecule; Lilly assumes full global development and commercialization responsibility. This is BioArctic's fourth BrainTransporter partnership, after collaborations with Bristol Myers Squibb (Alzheimer's), AbbVie, and an undisclosed partner. The deal signals continued big-pharma demand for blood-brain-barrier delivery platforms as neurodegeneration competition intensifies post-leqembi.
The full TRIUMPH-1 safety dataset clarified the retatrutide dysesthesia signal: 20.9% of patients on 12 mg reported tingling, tenderness, or altered sensation, versus 8.8% at 9 mg and 0.7% on placebo. The signal is dose-dependent, generally mild to moderate, and Lilly says it is being monitored across all ongoing TRIUMPH trials. The data sit alongside the arrhythmia signal (7/403 retatrutide, 3 MACE versus 0 placebo) that STAT flagged on June 6 and now constitute the field's main retatrutide-specific safety conversation.
BioPharma Dive's June 8 ADA wrap framed the meeting's competitive sort: Lilly reinforced its lead with retatrutide (28.3%) and Foundayo's head-to-head win over oral semaglutide; Pfizer's berobenatide emerged as 'foundational' with the monthly-dosing differentiation; Roche's enicepatide drew 'me-too' framing from RBC's Trung Huynh ('does little to differentiate enicepatide from its peers'). Novo Nordisk lost ground after CagriSema missed non-inferiority versus its target competitor on some endpoints. Lilly closed about 4.5% higher Monday on the data; Novo fell 3.46%.
Lilly presented full Phase 3 data from the ACHIEVE program in type 2 diabetes at ADA 2026's Monday symposium. In the head-to-head ACHIEVE-3 trial, Foundayo (orforglipron) beat oral semaglutide across the primary and all key secondary endpoints, with 37.1% of patients on the highest Foundayo dose reaching HbA1c under 5.7% (normal range) versus 12.5% on the highest oral semaglutide dose tested. ACHIEVE-2 compared Foundayo to dapagliflozin; ACHIEVE-5 added it to insulin glargine. Lilly plans to submit Foundayo for FDA T2D approval by end of Q2 under the Commissioner's National Priority Voucher.
At Saturday's Phase 3 retatrutide symposium, Lilly presented the full TRIUMPH-1 dataset in 2,339 adults with obesity or overweight without diabetes. Mean weight loss reached 28.3% (70.3 lbs) at 12 mg over 80 weeks, with 45.3% of 12 mg patients reaching at least 30% loss; in a BMI ≥35 extension, the 12 mg arm hit 30.3% (85.0 lbs) at 104 weeks. Cardiometabolic side effects included up to 41.0% triglyceride drop, 24.2% non-HDL drop, 12.3 mmHg systolic blood pressure drop, and 24.1 cm waist reduction. The 4 mg dose still produced 19.0% weight loss with discontinuation below placebo.
The first Phase 3 retatrutide diabetes trial, TRANSCEND-T2D-1, was simultaneously published in The Lancet and presented at the June 6 symposium. In adults with type 2 diabetes inadequately controlled on lifestyle alone, retatrutide produced A1C reductions of up to 2.0 percentage points and weight loss of up to 16.8% (36.6 lbs) at 40 weeks, with up to 46% achieving a normal A1C — a threshold rare in diabetes treatment trials. Systolic blood pressure and lipid markers improved across doses.
Beyond TRIUMPH-1 and TRANSCEND-T2D-1, Lilly confirmed at ADA that seven additional Phase 3 retatrutide readouts span obesity, type 2 diabetes, osteoarthritis, obstructive sleep apnea, chronic low-back pain, metabolic dysfunction-associated steatotic liver disease (MASLD), and the cardiometabolic-outcomes program. The MASLD readout is on track for H1 2027, and TRIUMPH-OUTCOMES (cardiovascular events in a 10,000-patient population) anchors the late-2027 timeline.
Eli Lilly will present full data on retatrutide, Foundayo (orforglipron), and Mounjaro at the American Diabetes Association's 86th Scientific Sessions. The triple agonist retatrutide lowered A1C by up to 2.0% and drove 16.8% weight loss, about 36.6 lbs at the 12 mg dose, over 40 weeks in its first Phase 3 diabetes trial, TRANSCEND-T2D-1. Oral Foundayo beat oral semaglutide head-to-head with 73.6% greater relative weight loss and an A1C reduction of up to 1.7% against 0.8% for dapagliflozin.
Published May 12 in Nature Medicine and presented at ECO 2026, the first-of-its-kind ATTAIN-MAINTAIN trial (NCT06584916) tested whether adults who had already lost substantial weight on Wegovy or Zepbound could maintain it after switching to once-daily orforglipron. Over 52 weeks, the semaglutide-switch group regained an average of 1 kg and the tirzepatide-switch group an average of 5 kg, with most cardiometabolic gains preserved. Carel le Roux and Louis Aronne led the analysis.